With over 400 million persistent sufferers, India is without doubt one of the world’s largest medication markets. However whereas most e-pharmacies chase velocity, affordability stays the actual problem. Truemeds took a distinct route: serving to sufferers change to lower-cost substitutes, a guess now paying off with new funding at about 4 instances its earlier valuation.
The six-year-old startup has raised $85 million in a brand new spherical that features $65 million in major and $20 million in secondary funding led by Accel, together with participation from Peak XV Companions. TechCrunch first reported on Accel’s talks to again Truemeds final 12 months. Present traders WestBridge Capital and InfoEdge Ventures, additionally participated.
The recent spherical has boosted Truemeds’ valuation to over $400 million, up from the $110 million in its final spherical two years in the past.
Based in 2019, Truemeds entered the market at a time when India’s on-line pharmacy house was already crowded with main gamers providing steep reductions on branded generics. However a few of these firms struggled to maintain early momentum — Prosus Ventures-backed PharmEasy, as an illustration, noticed its valuation drop from a peak of $5.6 billion to underneath $600 million, whereas 1mg was acquired by Tata Digital, a part of the Tata Group. As a substitute of competing head-on, Truemeds’ founders selected to give attention to a comparatively area of interest phase: generic medicines.
“There isn’t any solution to educate the consumer which you could have extra reasonably priced choices in the event you can’t afford these medicine,” mentioned Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. “That’s the place we felt that no one within the worth chain was working in direction of that, and we will bridge that hole.”
The Mumbai-based recommends generic alternate options to customers for the branded medicines they want. This finally helps customers get monetary savings, as generic medicine are usually extra reasonably priced than their branded variations because of price efficiencies of their growth course of.
Truemeds says its differentiated method has paid off, with income rising over 66% year-over-year to ₹5 billion ($57 million) within the final monetary 12 months. The startup says it retains greater than 15% of its income after 12 months and now serves a mean of 500,000 prospects every month, with a complete of three million prospects so far. Furthermore, it says it now serves over 20,000 postal codes throughout the nation, with greater than 75% of its prospects coming from tier-2 cities and past.
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Nonetheless, educating prospects about alternate options to their prescribed medicines — and convincing them to modify from branded medicine to generics — stays a problem.
“Since you get anchored to your prescribed model’s worth, and whenever you instantly see a cheaper price, you wish to know why it’s low,” Nayyar instructed TechCrunch.
Rising reductions whereas rivals in the reduction of
Whereas at present’s e-pharmacies chase velocity over financial savings, the sector’s early playbook was completely different. On-line pharmacies in India used to supply reductions of as much as 25% to draw prospects. Nonetheless, Nayyar mentioned this dropped to twenty% after which 15% — the brand new common — as most burned money to accumulate new prospects and pivoted to sooner supply as their predominant differentiator.
In the meantime, Truemeds has gone in the wrong way, growing its common reductions from 29% to 32% within the final 12 months. For a mean consumer who switches manufacturers on the platform, financial savings attain 47% on their medication, says the corporate.
This comes from Truemeds’ deep procurement relationships with pharma firms, the place the startup makes use of its know-how to provide producers higher demand visibility, serving to them plan manufacturing extra effectively for upcoming quarters, he mentioned.
The startup additionally depends by itself logistics in among the main cities it operates in and makes use of low-cost logistics companions for the remaining.
“We consider that our four-hour supply mannequin is greater than enough from a persistent affected person’s perspective,” mentioned Nayyar. “You’re capable of do extra deliberate purchases that method, however we wish to do it in probably the most environment friendly method, and cross increasingly reductions to the tip consumer quite than [focus on] the quickest supply for that matter.”
Subsequent up: AI-powered customization and doorstep diagnostics
As Truemeds must persuade prospects to decide on generics over branded medicines, it goes by means of deeper consultations with them. It already conducts 10-12 million consultations per 12 months. The startup has developed an algorithm over time that appears at varied parameters to exactly recommend alternate options to the branded medicine a buyer calls for. It considers nuances resembling whether or not the medication is sugar-coated whether it is for a younger affected person, the place it’s manufactured, and whether or not the plant is GMP-certified, amongst others. The startup additionally has a chatbot to deal with some consumer queries shortly.
Rather more is on the roadmap. The corporate plans to develop an AI-based system that customizes conversations primarily based on prospects’ habits and former interactions with generic alternate options. It’s additionally opening a Bengaluru workplace whereas dedicating at the very least 20% of its capital to engineering and product growth.
Past medicines, Truemeds is plotting to enter diagnostics by means of partnerships with nationwide pathology labs, planning to pilot lab testing providers in some tier-2 cities within the subsequent three to 4 months.
“The first mission stays the identical, which is making healthcare reasonably priced for the tip consumer,” the co-founder mentioned. “It began with medicines. Now that the mannequin is getting established, we’re going to preserve scaling that. Concurrently, we additionally wish to see if we will do one thing comparable on the diagnostics entrance, the place we might be the bottom price supplier of at the very least the commonest exams.”
The startup additionally plans to extend its success heart rely by 300% — from 19 at the moment — over the subsequent 12 months, aiming to deepen its presence in current markets.
Earlier than this spherical, Truemeds raised $50 million and nonetheless has 30–35% of that capital within the financial institution, Nayyar mentioned.
The startup has a workforce of two,800 folks, with 250 primarily based in its Mumbai workplace.
